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EXECUTIVE SUMMARY 
________________________________________________________ 
 
According to Article 2 of its constitution, the World Health Organization has a mandate from 
its Member States to develop, establish, and promote international standards with respect to 
food, biological, pharmaceutical and similar products. 
It was not until the disaster caused by thalidomide in 1961 that the first systematic 
international efforts were initiated to address drug safety issues. At that time many thousands 
of congenitally deformed infants were born as the result of exposure in utero to an unsafe 
medication promoted for use by pregnant mothers.  
Recent drug recall cases as VIOXX® and Viracept ®, show the importance of conducting 
post-marketing studies to assess drug safety and tolerability on a continuous basis to control 
for potential Adverse Drug Reactions (ADR).  VIOXX® was withdrawn from the market in 
2004 because there was sufficient evidence that the drug raised the risk of myocardial 
infarction.  
Pharmacovigilance is described by the WHO as the science and activities relating to the 
detection, assessment, understanding and prevention of adverse effects or any other possible 
drug-related problems. ADRs are said to account for 3% of deaths in the developed world, 
where more reliable mechanisms and structures are in place to ensure drug safety.    
In the recent years there have been significant increases in funding for the development of 
new formulations for “Drug Neglected Diseases” as disease burden and resistance to previous 
formulations (in the case of malaria) have increased. Many international, public, private and 
philanthropic organizations are devoting significant amounts of funding to the development 
of new drugs (more than US$250 million in 2006) as well as to subsidies and other strategies 
to increase the degree of coverage for these vital treatments.  
The constrained conditions in which these treatments are being taken include: patients might 
take the medication without a prescription, or without any interaction with qualified 
physicians or health professionals; lack of information or effective communication in drug 
safety and tolerability; weak or nonexistent formal structures for surveillance and drug 
monitoring. Thus it is of primary importance to invest in surveillance and safety assessment 
studies and also to reinforce the existent capabilities of a country to ensure drug safety.       
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When conducting pharmacovigilance studies one aims to establish a causal relationship 
between a certain Adverse Event (AE) and a given treatment. The dilemma of missing 
counterfactuals is that one cannot observe both scenarios of the individual under treatment 
and without it, which would be needed to conclude beyond reasonable doubt that the given 
AE was caused by the treatment and not by any background variable. Therefore, the design of 
an observational study should include strategies to control for the effect of confounding 
variables. This could help to isolate the effects of the drug itself, or block the effect of the 
other attributes, in order to assess direct cause-effect relationships.     
This research looks into design strategies for a country-wide Cohort Event Monitoring study 
on pharmacovigilance from a sampling perspective, to control for confounders and achieve a 
certain degree of statistical robustness by  
 Determining a cohort size: This research explores different methodologies to 
determine the optimal size of a cohort of patients in order to draw statistical inferences 
with a certain confidence level. 
 Proposing methods to reduce biases: If a sampling strategy different from pure 
random sampling is selected, what are the potential biases in the sample and how could 
one could reduce them when designing a study?  
 Designing a sampling strategy: Once a cohort size is targeted, how to collect that data 
in order to extrapolate the results for a whole population and how to control for 
confounding factors. This is achieved by techniques such as cluster sampling and 
stratified sampling to select sentinel sites for AEs data collection.  
 
Once the framework was built, a case study based on field research by the author for the 
implementation of a Cohort Event Monitoring study in Tanzania was developed. Different 
sampling strategies were applied and compared in order to further evaluate the applicability 
and robustness of the techniques proposed.   
The models were developed using the mathematical programming language LINGO by 
solving integer optimization programs that aimed to reduce the number of sentinel sites 
selected while fulfilling a target cohort size and achieving a significant level of 
representativeness of the country’s population. That is, according to a certain criteria such as 
demographics, incidence of disease, socio-economic profile, and so forth, select sentinel sites 
that would reflect the diversity of a population. Other statistical analysis tools such as SPSS 
were used in the intermediate data analysis phases in order to develop these models.   
This work shows that the utilization of statistical sampling techniques commonly used in 
market research, quality control or political polling is also viable and applicable to 
pharmacovigilance. Moreover the use of such techniques would positively impact the 
credibility of the study and the robustness of its results.   
 
 
 
 
 
 
